-
Mashup Score: 0
A $100,000 gift from UH Mānoa alumnus and philanthropist businessman Jay H. Shidler will help the UH Cancer Center increase public awareness of its work.
Source: www.uhfoundation.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Norgine seeks approval for high-risk neuroblastoma treatment - 11 day(s) ago
Norgine has sought approval for eflornithine (DFMO) for the treatment of patients with high-risk neuroblastoma (HRNB).
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
Source: www.businesswire.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0United States-Japan Joint Leaders’ Statement | The White House - 12 day(s) ago
Global Partners for the Future Over the course of the last three years, the U.S.-Japan Alliance has reached unprecedented heights. We arrived at this historic moment because our nations, individually and together, took courageous steps to strengthen our collective capacity in ways that would have seemed impossible just a few years ago. Today, we, President…
Source: www.whitehouse.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0未来の医師117 (上野直人 キャリア50:50) - 12 day(s) ago
114 未来の医師への贈りもの Present to Future Doctors上野直人University of Hawaii Cancer Center「50:50」(Cancer Doctor, Cancer Researcher, Cancer Survivor)(UHCC)(Self awarene…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy - 23 day(s) ago
Abstract. Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. Patients and Methods: Patients with a complete response (CR), partial response (PR), or stable disease (SD) after at least 3 cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression. Pembrolizumab (200 mg) was administered every 3 weeks until disease progression, intolerable toxicity, or 2 years of pembrolizumab exposure. The endpoints included the 4-month disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and response biomarkers in the blood. Resul
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3UH biomedical research grants pumps millions into state economy | University of Hawaiʻi System News - 29 day(s) ago
UH brought in $58 million in federal biomedical research grants to the state in fiscal year 2023.
Source: www.hawaii.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Free skin cancer checks goes on the road around Oʻahu | University of Hawaiʻi System News - 1 month(s) ago
The new Skin ✓ Van is the first of its kind in Hawaiʻi and will make its debut on April 20.
Source: www.hawaii.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41Withdrawn Oncology /Hematologic Malignancies Accelerated Approvals - 1 month(s) ago
No longer FDA-approved accelerated approvals (AAs) for malignant hematology and oncology indications
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
We, @UHCancerCenter, appreciate Mr. Shidler's support in making a major impact on cancer patients and the community through multiple new initiatives. The cancer center provides excellent clinical care through our innovative research. https://t.co/hBko2gA7S1 https://t.co/3hwutwWODR